Myocardial injury associated with chronic hepatitis C: Clinical types and pathogenetic components


Cite item

Full Text

Abstract

Heart injury is one of the extrahepatic manifestations of chronic hepatitis C (CHC). The paper gives Russian and foreign authors’ data on a relationship between CHC and myocardial injury. It discusses different pathogenetic components (the direct effect of the virus, immunological components), through which hepatitis C virus can induce myocarditis and cardiomyopathies in patients with CHC.

References

  1. Matsumori A. Hepatitis C Virus Infection and Cardiomyopathies. Circ Rec. 2005;96:144-147. doi: 10.1161/01.res.0000156077.54903.67.
  2. Игнатова Т.М., Апросина З.Г., Серов В.В. и др. Внепеченочные проявления хронического гепатита С. Терапевтический архив. 1998;11:9-16.
  3. Игнатова Т.М., Апросина З.Г., Белокриницкая О.А. и соавт. Миокардит, полимиозит и синдром Рейно у больной хроническим гепатитом С. Терапевтический архив. 1999;12:56-58.
  4. Крель П.Е., Апросина З.Г., Белокриницкая О. А. и соавт. Миокардит при хроническом активном гепатите. Клиническая медицина. 1989;2:78-83.
  5. Никитин И.Г., Сторожаков Г.И. Хронические HBV, HCV, HDV — гепатиты — системные инфекции. Терапевтический архив. 1998;2:80-82.
  6. Фомин В.В., Никулкина Е.Н., Седов В.П., Гирина С.С., Долецкий А.А., Моисеев С.В. Апикальная гипертрофическая кардиомиопатия, ассоциированная с HCV-инфекцией. Терапевтический архив. 2011;1:24-29.
  7. Kelbaek H, Eriksen J, Brynjolf I et al. Cardiac performance in patients with asymptomatic alcoholic cirrhosis of the liver. Am J Cardiol. 1984;54(7):852-855. doi: 10.1016/s0002-9149(84)80220-9.
  8. Wong F, Liu P, Lilly L et al. Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. Clin Sci (Lond). 1999;97(3):259-267. doi: 10.1042/cs0970259.
  9. Pozzi M, Carugo S, Boari G et al. Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. Hepatology. 1997;26(5):1131-1137. doi: 10.1002/hep.510260507.
  10. Конышева А.А., Сагинова Е.А, Моисеев C.В., Краснова Т.Н., Абдурахманов Д.Т. Диастолическая дисфункция миокарда и изменение интервала Q—T при хроническом гепатите C. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2012;22(6):38-43.
  11. Лопаткина Т.Н., Стрижаков Л.А., Конышева А.А., Танащук Е.Л., Таранова М.В., Моисеев С.В. Варианты поражения сердца при хроническом гепатите С. Клиническая фармакология и терапия. 2014;4:90-93.
  12. Richardson P, McKenna W, Bristow M et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology task forse on the definition and classification of cardiomyopathies. Circulation. 1996;93:841-842. doi: 10.1161/01.cir.93.5.841.
  13. Matsumori A. Animal model: pathological findings and therapeutic consideration. In Banatvala JE. ed. Viral Infection of the Heart. London, UK: E. Arnold; 1993:351-362. doi: 10.1007/978-3-642-77891-9_31.
  14. Дерюгин М.В., Бойцов С.А. Хронические миокардиты. Элби-СПб; 2005.
  15. Благова О.В., Недоступ А.В., Коган Е.А., Сулимов В.А. От «идиопатической» мерцательной аритмии к постановке нозологического диагноза. Клинические разборы в факультетской терапевтической клинике им. В.Н. Виноградова. Редкие и диагностически трудные заболевания в клинике внутренних болезней. М.: ГЭОТАР-Медиа; 2012.
  16. Недоступ А.В., Благова О.В., Коган Е.А., Сулимов В.А. Миокардиальный васкулит: путь к диагнозу, клинические варианты, попытки патогенетической терапии. Клинические разборы в факультетской терапевтической клинике им. В.Н. Виноградова. Редкие и диагностически трудные заболевания в клинике внутренних болезней. М.: ГЭОТАР-Медиа; 2012.
  17. Kawano H, Kawai S, Nashijo T et al. An autopsy case of hypertrophic cardiomyopathy with pathological findings suggesting chronic myocarditis. Jpn Heart J. 1994;35:95-105. doi: 10.1536/ihj.35.95.
  18. Matsumori A, Matoba Y, Sasyama S. Dilated cardiomyopathy associated with hepatitis virus infection. Circulation. 1995;92:2519-2525. doi: 10.1161/01.cir.92.9.2519.
  19. Matsumori A, Matoba Y, Nishino R et al. Detection of hepatitis C virus RNA from the heart of patient with hypertrophic cardiomyopathy. BiochemBiophys Res Commun. 1996;222:678-682. doi: 10.1006/bbrc.1996.0803.
  20. Okabe M, Fukuda K, Arakava K, Kikuchi M. Chronic variant of myocarditis associated with HCV — РНК. Circulation. 1997; 96:22-24. doi: 10.1161/01.cir.96.1.22.
  21. Teragaki M, Nishiguchi S, Takeuchi K et al. Prevalence of hepatitis C virus infection among patients with hypertrophic cardiomyopathy. Heart Vessels. 2003;18:167-170. doi: 10.1007/s00380-003-0705-0.
  22. Matsumori A. Role of hepatitis C virus in myocarditis and cardiomyopathies. Geriatr Cardiol. 2004;1:99-120. doi: 10.1007/3-540-30822-9_7.
  23. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet. 1997;350:430-436. doi: 10.1016/s0140-6736(97)03079-1.
  24. Matsumori A, Shimada T, Chapman NM, Tracy SM, Mason JW. Myocarditis and Heart Failure Associated With Hepatitis C Virus Infection. J Card Fail. 2006;12(4):293-298. doi: 10.1016/j.cardfail.2005.11.004.
  25. Аntonelli A, Ferri C, Ferrari S. High levels of circulating N-terminal pro-brain natriuretic peptide in patients with hepatitis C. J Viral Hepat. 2010;12:851-853. doi: 10.1111/j.1365-2893.2009.01237.x.
  26. Bristow MR. Tumor Necrosis Factor-α and Cardiomyopathy. Circulation. 1998;97:1340-1341. doi: 10.1161/01.cir.97.14.1340.
  27. Billingham ME, Tazelaar HD. The morphological progression of viral myocarditis. Postgrad Med J. 1986;62:581-584. doi: 10.1136/pgmj.62.728.581.
  28. O’Connell JB. The role of myocarditis in end-stage dilated cardiomyopathy. Texas Heart Inst J. 1987;14:268-275.
  29. Kawai C. From myocarditis to cardiomyopathy: mechanism of inflammation and cell death: learning from the past for the future. Circulation. 1999;99:1091-1100. doi: 10.1161/01.cir.99.8.1091.
  30. Neumann DA, Lane JR, Alen GS et al. Viral myocarditis leading to cardiomyopathy: do cytokines contribuye to pathogenesis? Clin Immunol Immunopathol. 1993;68:181-190. doi: 10.1006/clin.1993.1116.
  31. Gluck B, Schmidtke M, Merkle I et al: Persistent expression of cytokines in the chronic stage of CVB3-induced myocarditis in NMRI mice. J Mol Cell Cardiol. 2001;33:1615-1626. doi: 10.1006/jmcc.2001.1416.
  32. Matsumori A, Yamada T, Suzuki H et al. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J. 1994;72:561-566. doi: 10.1136/hrt.72.6.561.
  33. Satoh M, Tamura G, Segawa I et al: Expression of cytokine genes and presence of enteroviral genomic RNA in endomyocardial biopsy tissues of myocarditis and dilated cardiomyopathy. Virchows Arch. 1996;427:503-509. doi: 10.1007/bf00199511.
  34. Kelleher DM, Telfor SR, Criscione L et al. Cytokines in murine lyme carditis: Th1 cytokine expression follows expression of proinflammatory cytokines in a susceptible mouse strain. J Infect Dis. 1998;177:242-246. doi: 10.1086/517364.
  35. Calabrese F, Carturan E, Chimenti C et al. Overexpression of tumor necrosis factor (TNF) alpha and TNF-alpha receptor I in human viral myocarditis: clinicopathologic correlations. Mod Pathol. 2004;17:1108-1118. doi: 10.1038/modpathol.3800158.
  36. Torre-Aminone G, Kapadia S, Lee J et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation. 1996;93:704-711. doi: 10.1161/01.cir.93.4.704.
  37. Bryant D, Becker L, Richardson J et al. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation. 1998;97:1375-1381. doi: 10.1161/01.cir.97.14.1375.
  38. Torre-Aminone, G, Kapadia S, Lee J et al. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation. 1995;92:1487-1493. doi: 10.1161/01.cir.92.6.1487.
  39. Krown KA, Yasui K, Brooker MJ et al. TNF alpha receptor expression in rat cardiac myocytes: TNF alpha inhibition of L-type Ca2+ current and Ca2+ transients. FEBS Lett. 1995;376:24-30.
  40. Hare JM, Keaney JF Jr, Balligand JL et al. Role of nitric oxide in parasympathetic modulation of beta-adrenergic myocardial contractility in normal dogs. J Clin Invest. 1995;95:360-366. doi: 10.1172/jci117664.
  41. Hong X, Yu RB, Sun NX et al. Human leukocyte antigen class II DQB1*0301, DRB1*1101 alleles and spontaneous clearance of hepatitis C virus infection: a meta-analysis. World J Gastroenterol. 2005;11:7302-7307. doi: 10.3748/wjg.v11.i46.7302.
  42. Naruse TK, Inoko H. HLA and hepatitis C virus positive cardiomyopathy. Nippon Rinsho. 2000;58:212-217.
  43. Shichi D, Kikkawa EF, Ota M et al. The haplotype block, NFKBIL1-ATP6V1G2-BAT1-MICB-MICA, within the class III-class I boundary region of the human major histocompatibility complex may control susceptibility to hepatitis C virus-associated dilated cardiomyopathy. Tissue Antigens. 2005;66:200-208. doi: 10.1111/j.1399-0039.2005.00457.x.
  44. O’Garra N, Robinson D. Development and function of T helper 1 cells. Adv Immunol. 2004;83:133-162.
  45. Izumi T, Takehana H, Matsuda S et al. Experimental autoimmune myocarditis and its pathomechanism. Herz. 2000;25(3):274-278. doi: 10.1007/s000590050020.
  46. Mourad W, Al-Daccak R, Chatila T, Geha RS: Staphylococcal superantigens as inducers of signal transduction in MHC class II-positive cells. Semin Immunol. 1993;5:47-55. doi: 10.1006/smim.1993.1007.
  47. Mourad W, Mehindate K, Schall TJ, McColl SR. Engagement of major histocompatibility complex class II molecules by superantigenes induces inflammatory cytokines gene expression in human rheumatoid fi-broblast-like synoviocytes. J Exp Med. 1992;175:613-616. doi: 10.1084/jem.175.2.613.
  48. Li H, Lera A, Malchiodi EL, Mariuzza RA. The structural basis of T cell activation by superantigens. Annu Rev Immunol. 1999;17:435-466. doi: 10.1146/annurev.immunol.17.1.435.
  49. Al-Daccak R, Mehindate K, Hebert J et al. Mycoplasma arthritidis-derived superantigen induces proinflammatory monokine gene expression in the THP-1 human monocytic cell line. Infect Immun. 1994;62:2409-2416.
  50. Mehindate K, Al-Daccak R, Schall TJ, Mourad W. Induction of chemokine gene expression by major histocompatibility complex class II ligands in human fi broblast-like synoviocytes. Differential regulation by interleukin-4 and dexamethasone. J Biol Chem. 1994;269:32063-32069.
  51. Alvarez-Ossorio L, Johannsen M, Alvarez-Ossorio R et al. Cytokine induction by Micoplasma arthritidis-derived superantigen (MAS), but not TSST-1 or SEC-3, is correlated to certain HLA-DR types. Scand J Immunol. 1998;47:43-47. doi: 10.1046/j.1365-3083.1998.00252.x.
  52. Rink L, Nicklas W, Luhm J et al. Induction of proinflammatory cytokine network by Mycoplasma arthritidis-derived superantigen (MAS). J Interferon Cytokine Res. 1996;16:861-868. doi: 10.1089/jir.1996.16.861.
  53. Matsumori A, Sasayama S. Never Aspects of Pathogenesis of Heart Failure: Hepatitis C virus infection in myocarditis and cardiomyopathy. J Card Fail. 1996;2(4 Suppl.):187-194. doi: 10.1016/s1071-9164(96)80076-5.
  54. Frustaci A, Calabrese F, Chimenti C et al. Lone Hepatitis C virus Myocarditis responsive to immunosuppressive therapy. Chest. 2002;122:1348-1356. doi: 10.1378/chest.122.4.1348.
  55. Omura T, Yoshiyama M, Hayashi T et al. Core protein of hepatitis c virus induced cardiomyopathy. CircRes. 2005;96(2):148-150. doi: 10.1161/01.res.0000154263.70223.13.
  56. Meldrum DR, Dinarello CA, Cleveland JC Jr et al. Hydrogen peroxide induces tumor necrosis factor alpha-mediated cardiac injury by a P38 mitogen-activated protein kinase-dependent mechanism. Surgery. 1998;124(2):291-296. doi: 10.1016/s0039-6060(98)70133-3.
  57. Korenaga M, Okuda M, Otani K et al. Mitochondrial dysfunction in hepatitis C. J Clin Gastroenterol. 2005;39(4 Suppl.2):162-166. doi: 10.1097/01.mcg.0000155517.02468.46.
  58. Okuda M, Li K, Beard MR, Showalter LA et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology. 2002;122(2):366-375. doi: 10.1053/gast.2002.30983.
  59. Korenaga M, Wang T, Li Y et al. Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. J Biol Chem. 2005;280(45):37 481-37 488. doi: 10.1074/jbc.m506412200.
  60. Taylor ER, Hurrell F, Shannon RJ et al. Reversible Glutathionylation of Complex I Increases Mitochondrial Superoxide Formation. J Biol Chem. 2003;278(22):19603-19610. doi: 10.1074/jbc.m209359200.
  61. Meldrum DR, Dinarello CA, Cleveland JC Jr et al. Hydrogen peroxide induces tumor necrosis factor alpha-mediated cardiac injury by a P38 mitogen-activated protein kinase-dependent mechanism. Surgery. 1998;124(2):291-296. doi: 10.1016/s0039-6060(98)70133-3.
  62. Ungvari Z, Gupte SA, Recchia FA et al. Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr Vasc Pharmacol. 2005;3(3):221-229. doi: 10.2174/1570161054368607.
  63. Sam F, Kerstetter DL, Pimental DR et al. Increased reactive oxygen species production and functional alterations in antioxidant enzymes in human failing myocardium. J Card Fail. 2005;11(6): 473-480. doi: 10.1016/j.cardfail.2005.01.007.
  64. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev. 2001;15(22):2922-2933.
  65. Baker SJ, Reddy EP. Modulation of life and death by the TNF receptor superfamily. Oncogene. 1999;17:3261-3270. doi: 10.1038/sj.onc.1202568.
  66. Adhihetty PJ, Hood DA: Mechanisms of Apoptosis in Skeletal Muscles. Basic Appl Myol. 2003;13(4):171-179.
  67. Klibanov OM, Gale SE, Santevecchi B. Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection. Ann Pharmacother. 2015;49(5):566-581. doi: 10.1177/1060028015570729.
  68. Sulkowski MS, Gardiner DF, Rodriguez-Torres M et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection N Engl J Med. 2014;370(3):211-221. doi: 10.1056/nejmx140011.
  69. Buti M, Llaneras J, Riveiro-Barciela M, Esteban R. Therapy for hepatitis C genotype 3: moving forward. J Viral Hepat. 2015;22(9):683-690. doi: 10.1111/jvh.12419.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies